Hoya Corp. v. Alcon Inc. — Six-Patent IOL Dispute Dismissed With Prejudice
Hoya Corporation and three affiliates sued Alcon Inc. and three affiliates in the Northern District of Texas, asserting six patents covering intraocular lens insertion technology against Alcon’s UltraSert device. After 1,162 days of litigation, both sides stipulated to dismissal with prejudice, each bearing its own fees and costs.
Three-year IOL patent battle ends in mutual walk-away
In December 2020, Hoya Corporation — joined by affiliates HOYA Lamphun Ltd., HOYA Medical Singapore Pte. Ltd., and Hoya Surgical Optics, Inc. — filed suit against Alcon Inc. and three Alcon entities in the Northern District of Texas. The complaint asserted six US patents relating to intraocular lens (IOL) insertion devices, with Alcon’s UltraSert preloaded IOL delivery system identified as the accused product. Chief Judge Barbara M. G. Lynn presided over the matter.
On 16 February 2024, both sides filed a stipulation pursuant to Federal Rules 41(a)(1)(A)(ii) and 41(c) dismissing all claims and counterclaims with prejudice. Alcon had asserted counterclaims — typical in patent cases of this scale — and those too were extinguished. The with-prejudice designation means neither side may resurrect these specific claims in a future action. Critically, the parties agreed that each would bear its own attorneys’ fees and costs, suggesting no financial concession was extracted by either side on that front.
The 1,162-day duration — spanning more than three years — indicates the case progressed well beyond early motion practice before resolution, consistent with claim construction, discovery, and potentially IPR proceedings having been completed or initiated before settlement talks concluded. The public record does not disclose licensing terms, royalty arrangements, or any cross-licensing element, which are common undisclosed features of negotiated dismissals at this stage. What drove final resolution remains unknown from the docket alone.
Filing to dismissal in 1162 days
Days litigated — over 3 years before stipulated dismissal
Stipulated dismissal with prejudice — all claims and counterclaims extinguished
Rule 41 stipulated dismissal: what it means in practice
The dismissal was filed under FRCP 41(a)(1)(A)(ii), which requires agreement of all parties, and 41(c), which applies the same framework to counterclaims. A stipulated dismissal of this kind signals that both sides negotiated an exit. It carries no court finding on the merits — the patents are neither validated nor invalidated by this order. The with-prejudice designation is the operative legal consequence.
Negotiated exit, no merits rulingWith prejudice: Hoya’s IOL claims against Alcon are permanently closed
Dismissal with prejudice operates as a final adjudication on the merits under res judicata principles. Hoya and its affiliates cannot refile these six patent claims against the Alcon entities for the same accused products. Alcon’s counterclaims — also dismissed with prejudice — are likewise barred. This mutual finality is consistent with a negotiated commercial resolution, even though no financial terms appear on the public docket.
Permanent bar on refilingEach party bears its own costs — no prevailing-party finding
The stipulation specifies that each party bears its own fees and costs, which forecloses any 35 U.S.C. § 285 ‘exceptional case’ fee motion. This mutual cost-bearing arrangement is a standard feature of negotiated patent settlements and suggests neither side sought to characterise the other’s litigation conduct as exceptional — or that any such argument was resolved as part of the overall deal.
No § 285 fee exposureAlcon’s counterclaims also extinguished — a symmetrical outcome
Alcon had asserted counterclaims — likely invalidity and non-infringement defenses styled as declaratory judgment counts, which is standard practice in multi-patent disputes of this kind. Their dismissal with prejudice alongside Hoya’s infringement claims produces a symmetrical outcome: neither party retains any live claim arising from this action. The scope of Alcon’s counterclaims is not disclosed in available public filings.
Symmetrical dismissalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Hoya Corp. | Company | Optics and ophthalmic device group — holder of US10039668B2 and 5 related IOL patentsSearch in Eureka ↗ |
| Defendant | Alcon, Inc. | Company | Global ophthalmic surgical device company; maker of the UltraSert preloaded IOL inserterSearch in Eureka ↗ |
| Plaintiff counsel | Geoffrey L. Smith | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Plaintiff counsel | Hidetada James Abe | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Plaintiff counsel | James Sze | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Plaintiff counsel | Katherine Lynn Burkhart | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Plaintiff counsel | Kerry Hartman | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Plaintiff counsel | Lauren L. Fornarotto | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Plaintiff counsel | Lindsay C. Church | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Plaintiff counsel | Madeline E. Byrd | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Plaintiff counsel | Mitchell G. Stockwell | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Plaintiff counsel | Natalie C. Clayton | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Plaintiff counsel | Siraj Abhyankar | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Plaintiff counsel | Theodore Stevenson , III | Attorney | Counsel for Hoya Corp.Search in Eureka ↗ |
| Defendant counsel | David Dyer | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Gregg F. LoCascio | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeanne M. Heffernan | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeremy A. Fielding | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Kelly Paresh Tripathi | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Mara L. Greenberg | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Mark C. Mclennan | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew Hershkowitz | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Nancy Kaye Horstman | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Noah Samuel Frank | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Peter Jason Evangelatos | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Ryan Kane | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Barbara M. G. Lynn | Chief Judge | Texas Northern District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The stipulation invokes FRCP 41(a)(1)(A)(ii) and 41(c) jointly, covering both plaintiff claims and defendant counterclaims in a single instrument. The phrase ‘dismissal with prejudice of all claims and counterclaims’ is deliberately all-encompassing — no carve-outs, no surviving claims, and no admission of liability by either party. The mutual cost-bearing clause closes the door on any post-dismissal fee litigation. This phrasing is consistent with a commercially negotiated resolution whose substantive terms remain confidential.
Six US Patents — Intraocular Lens Insertion Device Technology
The six patents asserted by Hoya span a cluster of US grants covering intraocular lens insertion device technology, with application dates ranging across the mid-2010s. IOL inserters — particularly preloaded systems — represent a critical interface in cataract surgery, controlling how a foldable artificial lens is delivered through a small incision. Hoya’s portfolio in this space reflects a strategy of layered patent protection across device configurations, delivery mechanisms, and operational features of the insertion system, consistent with how mature ophthalmic device groups protect core surgical platform technology.
For competitors and adjacent technology developers, this cluster of six granted patents signals that Hoya views preloaded IOL delivery as a strategic IP moat. The fact that Hoya pursued Alcon — the dominant global player in cataract surgery equipment — demonstrates willingness to enforce these rights against market leaders. Even with this specific case resolved, the underlying patents remain in force and potentially applicable to other IOL insertion products. Any company developing or commercialising preloaded IOL delivery systems should treat this portfolio as an active enforcement risk.
Should you run an FTO against Hoya’s IOL insertion device patents?
Any R&D team developing preloaded intraocular lens delivery systems, IOL insertion devices, or adjacent cataract surgery tools should treat Hoya’s six-patent portfolio as a priority FTO target. This litigation demonstrates that Hoya is prepared to assert these patents against commercial-scale competitors. The dismissal with prejudice resolved only this dispute — it does not limit Hoya’s ability to assert these patents against other parties or different products. Companies in the surgical optics supply chain, particularly those developing or sourcing preloaded IOL systems, face direct exposure.
PatSnap Eureka’s FTO Search Agent enables you to map your product’s feature set against the claims of all six Hoya patents simultaneously, identifying overlap risk before market entry. Claim-level monitoring alerts you if Hoya files continuations or divisionals that could extend coverage into adjacent device architectures. Given the multi-year enforcement timeline this case illustrates, early FTO analysis is significantly more cost-effective than reactive litigation defence.
Run a freedom-to-operate analysis on US10039668B2 to assess your product’s exposure
Run FTO in Eureka →Similar IOL device patent infringement cases in US federal courts
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the ophthalmic device IP landscape
Six patents, two major IOL players, three years of litigation — the resolution pattern here carries clear signals for competitors and IP teams in the ophthalmic surgical space.
Multi-patent IOL assertions create sustained litigation pressure
Hoya’s decision to assert six patents simultaneously against Alcon’s UltraSert reflects a portfolio bundling strategy common in medical device disputes. Defending against six patents in parallel significantly raises defendant costs and settlement leverage. Companies in the IOL insertion device space should audit their exposure across entire patent families, not individual patents.
Three-year runway before resolution: plan for discovery-stage endurance
At 1,162 days, this case ran well past typical early dismissal windows. Teams should expect claim construction, expert discovery, and potentially IPR proceedings before any commercial resolution becomes viable in complex ophthalmic device patent disputes. Budgeting and strategy should account for a multi-year horizon in comparable cases.
Hoya v Alcon — key questions answered
Hoya Corporation and three affiliates sued Alcon Inc. and three affiliates in the Northern District of Texas in December 2020, asserting six patents covering IOL insertion devices against Alcon’s UltraSert product. The case was dismissed with prejudice by joint stipulation on 16 February 2024, with each party bearing its own fees and costs.
Hoya asserted six US patents: US10039668B2, US9877826B2, US9901442B2, US9655718B2, US9907647B2, and US9980811B2. All relate to intraocular lens insertion device technology. The accused product was Alcon’s UltraSert preloaded IOL delivery system.
Dismissal with prejudice means Hoya and its affiliates are permanently barred from refiling the same infringement claims against the Alcon entities for the accused products. Under res judicata principles, the dismissal operates as a final adjudication. Alcon’s counterclaims were also dismissed with prejudice. No court made a finding on the merits of infringement or validity.
Neither party received a court ruling on the merits. The case was resolved by a joint stipulation of dismissal with prejudice under FRCP 41(a)(1)(A)(ii) and 41(c). No liability finding, damages award, or injunction was issued. The terms of any underlying commercial resolution, if one exists, are not disclosed in the public record.
The case lasted 1,162 days — approximately 3 years and 2 months — from filing in December 2020 to dismissal in February 2024. This duration suggests the litigation progressed through substantial procedural stages, potentially including claim construction briefing, fact and expert discovery, and possibly inter partes review proceedings, before the parties reached a negotiated resolution.
PatSnap Eureka searches patents and litigation data to answer instantly.